doubleblind
condit
group
volunt
total
alloc
random
take
intranas
solut
placebo
one
three
dose
highli
purifi
leucocyt
interferon
intranas
spray
twice
day
day
highest
dose
would
expect
protect
experiment
cold
treatment
discontinu
upper
respiratori
symptom
often
interferon
group
placebo
group
howev
possibl
distinguish
clinic
cold
placebo
lowdos
interferon
reaction
treatment
highdos
interferon
featur
reaction
treatment
protract
buildup
local
symptom
minor
epistaxi
none
volunt
highdos
interferon
thought
definit
cold
virus
isol
four
six
volunt
lowdos
interferon
definit
cold
previou
experi
also
shown
dose
insuffici
protect
experiment
rhinoviru
challeng
dose
interferon
appear
protect
viru
infect
caus
signific
unwant
effect
essenti
find
interferon
prepar
less
inflammatori
activ
interferon
consid
use
longterm
prophylact
common
cold
variou
prepar
leucocytederiv
rdnacderiv
human
alpha
interferon
ifna
given
intranas
protect
rhinoviru
coronaviru
cold
volunt
merigan
et
al
higgin
et
al
phillpott
et
al
studi
interferon
given
viru
challeng
evid
yet
exogen
interferon
affect
clinic
cours
cold
symptom
begun
interferon
use
prophylaxi
accept
public
may
treatment
would
taken
regular
basi
period
risk
howev
control
trial
mrc
common
cold
unit
salisburi
uk
volunt
treat
variou
interferon
prepar
challeng
salin
instead
viru
local
upper
respiratori
symptom
treat
placebo
suggest
interferon
may
caus
local
reaction
scott
support
observ
local
inflamm
intraderm
inject
monoclon
antibodypurifi
interferon
influenzalik
reaction
parenter
interferon
priestman
scott
et
al
dose
day
rdna
interferona
prevent
rhinoviru
cold
frequent
dose
requir
consist
protect
experiment
viru
challeng
time
day
phillpott
et
al
preliminari
largescal
prophylaxi
studi
therefor
toler
schedul
intranas
interferon
suffici
protect
experiment
viru
challeng
studi
healthi
volunt
four
week
studi
protocol
approv
ethic
committe
northwick
park
hospit
volunt
recruit
staff
clinic
research
centr
northwick
park
hospit
staff
student
harrow
colleg
higher
educ
middlesex
uk
volunt
screen
medic
histori
examin
upper
respiratori
tract
puls
blood
pressur
routin
haematolog
biochem
test
femal
urin
screen
human
chorion
gonadotrophin
volunt
clinic
signific
ill
abnorm
exclud
common
exclus
criterion
perenni
rhiniti
although
volunt
hay
fever
expect
activ
diseas
period
studi
marchapril
includ
studi
interferon
induc
pool
buffycoat
leucocyt
use
sendai
viru
partial
purifi
previous
describ
cantel
et
al
purif
done
affin
adsorpt
chromatographi
monoclon
antibodi
bound
sepharos
secher
burk
interferon
stabil
addit
twicereprecipit
human
serum
albumin
mgrnl
placebo
solut
phosphatebuff
salin
albumin
concentr
activ
placebo
prepar
test
extens
contamin
adventiti
agent
acut
toxic
group
mice
guinea
pig
final
prepar
given
volunt
contain
ngml
bacteri
endotoxin
limulu
lysat
assay
preserv
ad
interferon
activ
assay
human
bovin
cell
immunoradiometr
assay
use
secher
dilut
eluat
column
made
give
concentr
million
unit
mu
per
rnl
backtitr
dilut
sever
assay
leucocyt
interferon
standard
show
contain
muml
respect
solut
includ
placebo
indistinguish
suffici
solut
fourteen
day
treatment
dispens
steril
bottl
fit
nasal
spray
pump
dose
rnl
per
nostril
morn
even
thu
intend
daili
dose
interferon
nil
placebo
group
mu
group
b
mu
group
c
mu
group
spray
kept
home
domest
refriger
volunt
alloc
random
receiv
placebo
one
three
interferon
solut
assess
doubleblind
condit
cold
two
week
start
studi
exclud
volunt
seen
start
treatment
day
addit
volunt
ask
report
develop
three
upper
respiratori
symptom
hour
volunt
kept
daili
record
symptom
nil
mild
l
moder
sever
hour
visit
includ
pretrial
assess
volunt
use
standard
paper
tissu
blow
nose
collect
count
weigh
visit
volunt
assess
clinic
accord
schedul
use
mrc
common
cold
unit
bear
reed
suspect
interferon
might
caus
reaction
known
advanc
whether
would
possibl
distinguish
cold
reaction
treatment
discontinu
symptom
present
hour
time
two
clinic
assessor
gm
jko
judg
whether
syndrom
like
unlik
classic
cold
basi
clinic
experi
assess
independ
clinic
score
standard
practic
mrc
common
cold
unit
bear
reed
nasal
wash
throat
swab
cultur
hela
primari
baboon
kidney
mrc
mrc
cell
presenc
x
neutralis
unit
calf
antilymphoblastoid
interferon
neg
specimen
passag
throat
swab
cultur
streptococci
preand
posttrial
sera
volunt
examin
interferon
neutralis
activ
treatment
solut
contain
preserv
remnant
cultur
assess
frequenc
level
bacteri
contamin
random
sampl
treatment
remnant
also
assay
antivir
activ
establish
whether
treatment
lost
activ
seventythre
volunt
consid
suitabl
trial
five
cold
within
two
week
start
treatment
exclud
tabl
show
characterist
four
group
volunt
random
alloc
produc
imbal
characterist
might
influenc
outcom
sex
age
histori
hay
fever
smoke
previou
exposur
intranas
interferon
howev
number
small
obviou
influenc
factor
outcom
term
number
volunt
subsequ
discontinu
treatment
case
two
volunt
group
c
inadvert
prematur
end
therapi
follow
shortli
upper
respiratori
symptom
one
complet
day
treatment
develop
symptom
one
day
afterward
break
six
day
ten
day
treatment
develop
upper
respiratori
symptom
day
new
bottl
dispens
volunt
complet
day
treatment
unless
signific
symptom
definit
reaction
thought
unlik
cold
diagnos
given
highest
dose
interferon
none
given
placebo
p
fisher
exact
test
twotail
howev
differ
group
proport
volunt
stop
treatment
possibl
definit
cold
oppos
reaction
achiev
statist
signific
time
volunt
discontinu
treatment
group
present
use
life
tabl
figur
although
interferon
group
appear
wors
placebo
group
log
rank
analysi
reveal
signific
differ
group
p
signific
trend
increas
dose
p
nine
volunt
mild
symptom
discontinu
treatment
either
thought
volunt
trivial
merit
special
visit
fulfil
criteria
withdraw
treatment
cluster
symptom
day
indic
may
mild
cold
other
one
two
symptom
suggest
perenni
rhiniti
virus
isol
four
volunt
definit
cold
lowdos
interferon
viral
isol
neg
stop
highest
dose
interferon
although
streptococcu
lancefield
group
g
isol
throat
one
addit
four
virus
isol
twelv
volunt
includ
two
group
c
stop
treatment
prematur
cold
complet
withdraw
treatment
three
volunt
two
discret
upper
respiratori
ill
volunt
highdos
interferon
group
develop
upper
respiratori
symptom
stop
treatment
symptom
nine
volunt
placebo
lowdos
interferon
group
thought
cold
compar
five
highdos
interferon
assess
reaction
tabl
latter
mild
symptom
particularli
nasal
discomfort
mani
day
wherea
cold
show
high
clinic
score
one
two
day
secondli
seven
nine
patient
cold
clear
nasal
discharg
compar
one
five
reaction
thirdli
five
patient
reaction
prolong
bloodstain
nasal
secret
two
frank
epistaxi
compar
one
nine
cold
latter
volunt
report
tendenc
toward
nose
bleed
trial
volunt
stop
treatment
chang
mean
number
tissu
use
hour
trial
except
group
highest
dose
interferon
rise
pretrial
two
week
four
week
observ
small
parallel
rise
mean
nasal
secret
weight
durat
symptom
treatment
stop
volunt
cold
n
reaction
n
day
stop
treatment
four
bottl
use
treatment
cultur
return
laboratori
grew
organ
typic
commens
upper
respiratori
flora
interferon
solut
lose
activ
studi
period
posttreat
sera
fail
neutralis
antivir
effect
vitro
sixweek
period
studi
upper
respiratori
event
volunt
enter
trial
expect
seventeen
report
symptom
perhap
partli
introspect
engend
daili
report
symptom
anoth
group
record
minor
symptom
intermitt
trial
period
expect
regular
spray
substanc
nose
howev
innocu
might
caus
symptom
slight
rhinorrhoea
short
period
spray
five
clinic
cold
occur
fortnight
preced
start
trial
suggest
volunt
might
expect
develop
cold
subsequ
six
week
howev
addit
volunt
definit
clinic
cold
other
possibl
cold
treatment
posttreat
cold
six
volunt
appar
reaction
treatment
manifest
protract
symptom
nasal
discomfort
nose
bleed
without
much
rhinorrhoea
suggest
low
dose
interferon
might
protect
volunt
wild
oppos
experiment
viru
exposur
treatment
lowest
dose
interferon
clearli
fail
protect
clinic
cold
rhinovirus
coronavirus
isol
four
volunt
small
number
trial
allow
us
evalu
whether
small
dose
interferon
might
amelior
cold
rather
prevent
total
howev
highest
dose
caus
unwant
upper
respiratori
symptom
particularli
dri
uncomfort
nose
nose
bleed
previou
studi
dose
suffici
protect
rhinoviru
coronaviru
cold
clinic
definit
cold
group
virus
isol
neither
posttreat
cold
period
observ
group
found
rdna
given
nasal
spray
dose
mu
per
day
caus
local
symptom
week
administr
yet
highli
effect
protect
wild
rhinoviru
infect
farr
et
al
bett
et
al
histolog
nasal
mucos
biopsi
reveal
nonspecif
inflamm
ulcer
hayden
et
al
puriti
materi
togeth
result
singl
speci
leucocyt
interferon
suggest
exogen
interferon
caus
intranas
inflamm
whether
endogen
interferon
produc
cold
contribut
symptom
cold
matter
specul
preliminari
studi
show
minim
effect
dose
intranas
interferon
necessari
prevent
cold
caus
local
inflamm
given
week
fewer
half
volunt
could
continu
take
month
without
signific
discomfort
therefor
import
search
prepar
interferon
less
inflammatori
effect
altern
approach
use
highdos
interferon
short
time
contact
cold
herzog
et
al
pfeiffer
gmbh
gift
nasal
spray
pump
dr
rj
phillpott
dr
daj
tyrrel
help
advic
volunt
enthusiast
help
